Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
Castle Biosciences CEO Derek J. Maetzold reported a mix of option exercises and share sales in Castle Biosciences Inc. common stock. He exercised stock options to acquire 6,214 shares at a price of $2.3900 per share and sold 9,836 shares in open-market transactions at a weighted-average price of $20.8570 per share.
Part of the sales came from entities such as The Maetzold Descendants 2020 Trust, the Derek Maetzold 2020 Irrevocable Trust and several 2018 remainder trusts, while a portion was from his direct holdings, which totaled 21,479 shares after these transactions. All sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The filing reports multiple Rule 144-related dispositions of common stock by entities and trusts associated with Derek Maetzold, with sizeable blocks sold across March–May 2026. Representative transactions include a sale of 23,179 shares on 03/12/2026 and repeated smaller trust sales; proceeds are shown per trade.
Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of Castle Biosciences common stock at no purchase price.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the company’s next Annual Meeting of Stockholders following the grant date. After this award, Olson holds 11,766 RSUs directly, and the filing shows no additional option or derivative positions.
Goldberg Ellen reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Ellen Goldberg received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents one share of the company’s common stock, so this award covers 11,766 shares. Following the grant, she holds 11,766 RSUs directly.
The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award, not an open‑market share purchase or sale.
Harrison Miles reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Miles Harrison received a grant of Restricted Stock Units. On May 28, 2026, he was awarded 11,766 RSUs, each representing the right to receive one share of the company’s common stock. These RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. Following this award, his reported derivative holdings from this grant total 11,766 RSUs held directly.
Cotton Rodney reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Rodney Cotton received a grant of 11,766 Restricted Stock Units. Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next annual meeting of stockholders following the grant date.
Caple Kim reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Kim Caple received a grant of 11,766 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents one share of common stock, for a total underlying amount of 11,766 shares. The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. After this grant, Caple’s reported derivative holdings from this award total 11,766 RSUs.
BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.
CASTLE BIOSCIENCES INC director Daniel Bradbury received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders after the grant date. Following this award, Bradbury is reported as holding 11,766 RSUs directly.
Cole G Bradley reported acquisition or exercise transactions in this Form 4 filing.
Castle Biosciences director Cole G. Bradley received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of the company’s common stock, giving him 11,766 shares underlying this award after the transaction.
The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027 or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Castle Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected three Class I directors — Ellen Goldberg, Miles D. Harrison and Tiffany P. Olson — each to serve until the 2029 annual meeting, with support ranging from 14.4 million to 15.6 million votes in favor and 2.4 million broker non-votes. They also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 24.5 million votes for and minimal opposition. In advisory and related votes, stockholders approved the compensation of the company’s named executive officers, with about 21.3 million votes in favor versus 1.3 million against, and approved the non-employee director compensation policy by similar margins.